Shanghai Fuda Pharmaceutical Co., Ltd.

It has a strong blocking effect on the 5-hydroxytryptamine (5-HT2A) receptor and dopamine (DA1) receptor in the brain, and also has a blocking effect on the dopamine (DA4) receptor, and a weaker blocking effect on the dopamine (DA2) receptor. In addition, it has anticholinergic (M1), antihistamine (H1) and anti-α-adrenergic receptor effects, and rarely has extrapyramidal reactions. It generally does not cause an increase in blood prolactin. It can directly inhibit the ascending activation system of the brainstem reticular formation and has a strong sedative and hypnotic effect.

It participates in amino acid metabolism, synthesis of neurotransmitters, synthesis of collagen and tissue cell interstitial, can reduce the permeability of capillaries, accelerate blood coagulation, stimulate coagulation function, promote iron absorption in the intestine, promote the decrease of blood lipids, increase resistance to infection, participate in detoxification function, and has antihistamine effect and prevents the formation of carcinogens (nitrosamines).

This product belongs to the macrolide antibiotics, which is the ethyl succinate of erythromycin. It is more stable than erythromycin in gastric acid. It has antibacterial activity against Staphylococcus (except methicillin-resistant strains), all groups of streptococci and Gram-positive bacilli. Neisseria, Haemophilus influenzae, Bordetella pertussis, etc. are also sensitive to this product. This product also has antibacterial effects on various anaerobic bacteria except Bacteroides fragilis and Fusobacterium. It also has inhibitory effects on Legionella, Campylobacter fetus, some spirochetes, Mycoplasma pneumoniae, Rickettsia, Chlamydia and Chlamydia. This product is an antibacterial agent, but it also has a bactericidal effect on some bacteria at high concentrations. This product can penetrate the bacterial cell membrane and form a reversible combination with the 50S subunit of the bacterial ribosome near the donor site (P site), blocking the transfer RNA (t-RNA) from binding to the P site, and also blocking the displacement of the polypeptide chain from the acceptor site (A site) to the P site, thereby inhibiting bacterial protein synthesis.

This product is a fluoroquinolone antibacterial drug with a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacteria. It has good antibacterial activity against the following bacteria in vitro: most bacteria of the Enterobacteriaceae family, including Citrobacter, Enterobacter cloacae, Enterobacter aerogenes and other Enterobacter species, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. Norfloxacin also has antibacterial activity against multi-drug resistant bacteria in vitro. It also has good antibacterial effects on penicillin-resistant Neisseria gonorrhoeae, Haemophilus influenzae and Moraxella catarrhalis. Norfloxacin is a bactericide that acts on the A subunit of bacterial DNA helicase, inhibiting DNA synthesis and replication, leading to bacterial death.

Unspecified